Publications by authors named "Axel Hoos"

Claim this Profile
I
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Jane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, Axel Hoos

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.
Darrin D Stuart, Angel Guzman-Perez, Natasja Brooijmans, Erica L Jackson, Gregory V Kryukov, Axel Hoos

Cancer Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade.
Sapna Yadavilli, Jeremy D Waight, Sara Brett, Meixia Bi, Tianqian Zhang, Axel Hoos

Cancer Res Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Axel Hoos

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses .
Rocio Montes de Oca, Alireza S Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Axel Hoos

Mol Cancer Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industrializing engineered autologous T cells as medicines for solid tumours.
Cedrik M Britten, Aiman Shalabi, Axel Hoos

Nat Rev Drug Discov· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunodynamics of explanted human tumors for immuno-oncology.
Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, Safae Terrisse, Nicolas Voisin, Axel Hoos

EMBO Mol Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Paul G Richardson, Hans C Lee, Al-Ola Abdallah, Adam D Cohen, Prashant Kapoor, Axel Hoos

Blood Cancer J· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Axel Hoos

Lancet Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.
Weiyi Peng, Leila J Williams, Chunyu Xu, Brenda Melendez, Jodi A McKenzie, Axel Hoos

Clin Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.
Joshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, Nestor Concha, Robert Singhaus, Axel Hoos

Nature· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
Jong W Yu, Sabyasachi Bhattacharya, Niranjan Yanamandra, David Kilian, Hong Shi, Axel Hoos

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Partnership for Accelerating Cancer Therapies.
Rebecca G Baker, Axel X Hoos, Stacey J Adam, David Wholley, James H Doroshow

Cancer J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Axel Hoos

Blood Cancer J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of amidobenzimidazole STING receptor agonists with systemic activity.
Joshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, Nestor Concha, Robert Singhaus, Axel Hoos

Nature· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Axel Hoos

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The promise and challenges of immune agonist antibody development in cancer.
Patrick A Mayes, Kenneth W Hance, Axel Hoos

Nat Rev Drug Discov· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Axel Hoos

J Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Regulatory Environment of RNA-Based Vaccines.
Thomas Hinz, Kajo Kallen, Cedrik M Britten, Bruno Flamion, Ulrich Granzer, Axel Hoos

Methods Mol Biol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Bruce D Cheson, Stephen Ansell, Larry Schwartz, Leo I Gordon, Ranjana Advani, Axel Hoos

Blood· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Axel Hoos

Nat Rev Drug Discov· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.
Axel Hoos, Jedd D Wolchok, Rachel W Humphrey, F Stephen Hodi

Clin Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
David R Minor, Igor Puzanov, Margaret K Callahan, Bruce A Hug, Axel Hoos

Pigment Cell Melanoma Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Big opportunities for small molecules in immuno-oncology.
Jerry L Adams, James Smothers, Roopa Srinivasan, Axel Hoos

Nat Rev Drug Discov· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for the automated evaluation of Elispot assays.
Sylvia Janetzki, Leah Price, Helene Schroeder, Cedrik M Britten, Marij J P Welters, Axel Hoos

Nat Protoc· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis